AstraZeneca PLC (BCBA:AZN)

Market Cap	346.58T
Revenue (ttm)	67.33T
Net Income (ttm)	9.89T
Shares Out	n/a
EPS (ttm)	6,326.07
PE Ratio	35.06
Forward PE	16.76
Dividend	834.84 (1.53%)
Ex-Dividend Date	Aug 8, 2025

Volume	25
Average Volume	368
Open	55,050
Previous Close	54,800
Day's Range	54,450 - 55,050
52-Week Range	34,800 - 58,050
Beta	n/a
RSI	81.22
Earnings Date	Nov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD